Table 4

Comparison of patients at 2 years follow-up for 256 (90%) of patients who survived first year

Patients at 2 years follow-upNurse led n=112Usual care n=144
All patients n112144
 Measured p-urate <0.36 mmol/L n (%)89 (79%)54 (38%)
 Measured p-urate ≥0.36 mmol/L n1947
 Not measured p-urate n443
Patients without measured p-urate at 2 years n443
 Ongoing ULT n419
 Dose allopurinol mg/day mean309242
 No ongoing ULT n024
Ongoing ULT and measured p-urate at 2 years n110113
 p-urate <0.36 mmol/L n (%)89/110=81%53/113=47%
All patients with and without measured p-urate at 2 years n112144
 urate <0.36 mmol/L excluding extrapolated n8954
 Extrapolated to p-urate <0.36 mmol/l n81% of 4=347% of 19=9
 p-urate <0.36 mmol/L including extrapolated n (%)89+3=92 (82%)54+9=63 (44%)
ULT all types n (%)110 (98%)105 (73%)
 Allopurinol n (%)101 (92%)96 (67%)
 Allopurinol mg/day mean308235
 Febuxostat n (%)87
 Probenecid n (%)12
 No ULT n (%)2 (2%)39 (27%)
Mortality (all 286 patients at baseline)114172
 Number died <1 years n (%)2 (2%)28 (16%)
 Males n (%)2 (2%)15 (12%)
 Females n (%)0 (0%)13 (31%)
 Died <1 year and cancer at baseline n (%)0 (0%)6 (3%)
 Number died <2 years n (%)4 (4%)39 (23%)
 Males n (%)4 (4%)23 (18%)
 Females n (%)0 (0%)16 (38%)
 Died <2 years and cancer at baseline n (%)1 (1%)7 (4%)
  • Extrapolation of p-urate <0.36 mmol/L was based on known dose of allopurinol. Mortality figures are stated for all 286 patients included at baseline.

  • ULT, urate-lowering-therapy.